BeStock  
Markets › Compare › CYTK vs PTGX

CYTK vs PTGX

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
CYTK · Cytokinetics$50.78 ▼ 1.32%
PTGX · Protagonist Therapeutics$121.40 ▼ 2.11%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

6999128158187Nov 24, '25May 26, '26Nov 20, '26
  • CYTK -24.4%
  • PTGX +38.4%

Head to head

MetricCYTKPTGX
Price$50.78$121.40
Change today▼ 1.32%▼ 2.11%
Market cap$7.07B$7.92B
Return, 3 months-34.1%-21.5%
Return, year to date-20.1%+39.0%
Return, 1 year-22.4%+42.2%
P/E (TTM)–25.7
P/B-22.07.3
P/E percentile vs own 5y65th78th
Dividend yield––
Revenue growth (YoY, latest qtr)+2,356.5%+5,723.6%
Net profit growth (YoY)+37.9%+659.3%
Gross margin95.3%99.6%
Operating margin-625.2%58.6%
Net margin-686.6%62.0%
Return on equity–39.6%
Analyst target vs. price+111.3%+48.3%
Analyst buy share94%100%
RSI (14)3032
30-day volatility52.6%41.1%
Max drawdown, 1 year-41.8%-23.5%
Trend readStrong downtrendLeaning bearish
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • PTGX is the largest of the group by market value.
  • PTGX has returned the most over the past year.
  • PTGX is growing revenue fastest.
  • PTGX keeps the most profit per dollar of sales.
  • PTGX has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top